Drugs / Xanthohumol
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05463393 | Oct 2020 → Jan 2022 | COVID-19 | Medical University of Lublin | Suspended | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03735420 | Aug 2019 → May 2020 overdue | — | National University of Natural Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02432651 | Mar 2015 → Jun 2016 | disorder of defective peroxisome oxidative status | Oregon State University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04590508 | Oct 2020 → Aug 2024 overdue | Crohn disease | National University of Natural Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | xanthohumol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02432651 ↗ |
| Known as | Xantho-flav | ChEMBL registry synonym — accepted as the source's own label CHEMBL253896 ↗ |
| Modality | Small molecule | “Xanthohumol, a flavonoid from the hops plant (Humulus lupulus), has antioxidant and anti-inflammatory properties and may act as a prebiotic to the intestinal microbiota.” PMID 33028396 ↗ Oct 2020 |
| Route | Oral | “Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks” NCT02432651 ↗ |